270 related articles for article (PubMed ID: 19913822)
1. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
Schlomer BJ; Ho R; Sagalowsky A; Ashfaq R; Lotan Y
J Urol; 2010 Jan; 183(1):62-7. PubMed ID: 19913822
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma.
Gayed BA; Seideman C; Lotan Y
J Urol; 2013 Oct; 190(4):1181-6. PubMed ID: 23583531
[TBL] [Abstract][Full Text] [Related]
4. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.
Youssef RF; Schlomer BJ; Ho R; Sagalowsky AI; Ashfaq R; Lotan Y
Urol Oncol; 2012; 30(3):273-7. PubMed ID: 20451422
[TBL] [Abstract][Full Text] [Related]
5. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
6. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
7. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
[TBL] [Abstract][Full Text] [Related]
8. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal.
Kipp BR; Halling KC; Campion MB; Wendel AJ; Karnes RJ; Zhang J; Sebo TJ
J Urol; 2008 Apr; 179(4):1296-301; discussion 1301. PubMed ID: 18289582
[TBL] [Abstract][Full Text] [Related]
9. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
[TBL] [Abstract][Full Text] [Related]
10. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?
Seideman C; Canter D; Kim P; Cordon B; Weizer A; Oliva I; Rao J; Inman BA; Posch M; Herr H; Lotan Y
World J Urol; 2015 Sep; 33(9):1309-13. PubMed ID: 25420920
[TBL] [Abstract][Full Text] [Related]
12. Reflex UroVysion testing in suspicious urine cytology cases.
Ferra S; Denley R; Herr H; Dalbagni G; Jhanwar S; Lin O
Cancer; 2009 Feb; 117(1):7-14. PubMed ID: 19347824
[TBL] [Abstract][Full Text] [Related]
13. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent in situ hybridization as a predictor of relapse in urothelial carcinoma.
García-Peláez B; Trias I; Román R; Pubill C; Banús JM; Puig X
Actas Urol Esp; 2013; 37(7):395-400. PubMed ID: 23453297
[TBL] [Abstract][Full Text] [Related]
16. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
[TBL] [Abstract][Full Text] [Related]
17. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
[TBL] [Abstract][Full Text] [Related]
18. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
20. A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study.
Galván AB; Salido M; Espinet B; Placer J; Pijuan L; Juanpere N; Lloreta J; Solé F; Gelabert-Mas A
Cancer Cytopathol; 2011 Dec; 119(6):395-403. PubMed ID: 21717592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
